Alpha 2.0
Login Register
» Journals » Breast Cancer

Breast Cancer : the Journal of the Japanese Breast Cancer Society

Breast Cancer: The Journal of the Japanese Breast Cancer Society is a reputable scientific journal dedicated to advancing knowledge and understanding of breast cancer. It publishes high-quality research articles, reviews, and case studies, covering various aspects of breast cancer, including prevention, diagnosis, treatment, and survivorship. With a focus on the Japanese perspective, this journal serves as a valuable resource for researchers, clinicians, and healthcare professionals involved in breast cancer care and research.
Details
Abbr. Breast Cancer
Start 1994
End Continuing
Frequency Quarterly
p-ISSN 1340-6868
e-ISSN 1880-4233
Country Japan
Language English
Specialty Oncology
Metrics
h-index / Ranks: 5503 66
SJR / Ranks: 3463 1054
CiteScore / Ranks: 4260 5.60
JIF / Ranks: 2264 4.0
Recent Articles
31.
Efficacy and feasibility of neoadjuvant pembrolizumab plus chemotherapy for early-stage triple-negative and estrogen receptor low, HER2-negative breast cancer: a Japanese single-institution real-world study
Aoyama Y, Ozaki Y, Kizawa R, Masuda J, Kawai S, Kurata M, et al.
Breast Cancer . 2024 Dec; 32(2):329-336. PMID: 39644440
Background: Neoadjuvant pembrolizumab plus chemotherapy and adjuvant pembrolizumab have been established as the optimal systemic therapies for patients with early stage triple-negative breast cancer (TNBC); however, their efficacy and feasibility...
32.
A 5-year review of genomic medicine in breast cancer: insights from C-CAT data on 3776 Japanese patients
Morita M, Tsunashima R, Yoshinami T, Ishida M, Iwasaku M, Kitano S, et al.
Breast Cancer . 2024 Dec; 32(2):314-328. PMID: 39630210
Background: In Japan, despite 5 years since CGP tests were covered by insurance in 2019, low drug accessibility rates remain a critical issue. We evaluated drug accessibility in 3776 breast...
33.
Prospective study of once-daily accelerated partial breast irradiation using 3-dimensional conformal external beam radiotherapy for Japanese women: 12-year outcomes, toxicity, and cosmesis
Takahashi K, Kagami Y, Yoshimura R, Morota M, Murakami N, Nakamura S, et al.
Breast Cancer . 2024 Dec; 32(1):197-207. PMID: 39630209
Background: To analyze in a prospective study the long-term safety and efficacy of 3-dimensional conformal radiotherapy (3D-CRT) to deliver accelerated partial breast irradiation (APBI) for Japanese women with early breast...
34.
The role of C1orf50 in breast cancer progression and prognosis
Otani Y, Tanaka A, Maekawa M, Pena T, Rogachevskaya A, Ando T, et al.
Breast Cancer . 2024 Nov; 32(2):292-305. PMID: 39604563
Although the prognosis of breast cancer has significantly improved compared to other types of cancer, there are still some patients who expire due to recurrence or metastasis. Therefore, it is...
35.
Adjuvant chemotherapy in T1a/bN0 breast cancer with a high 21-gene recurrence score (> 25): a 10-year follow-up in a real-world cohort
Katz D, Feldhamer I, Wolff-Sagy Y, Goldvaser H, Hammerman A, Goldstein D
Breast Cancer . 2024 Nov; 32(2):286-291. PMID: 39602054
Background: In ER + /HER2- early breast cancer (BC), 21-Gene Recurrence Score (RS) > 25 indicates high-risk of distant-recurrence and predicts benefit from adjuvant chemotherapy (aCT) regardless of tumor-size. However,...
36.
The complex role of regulatory cells in breast cancer: implication for immunopathogenesis and immunotherapy
Guo R, Wang P
Breast Cancer . 2024 Nov; 32(2):227-241. PMID: 39589625
Breast cancers (BCs) are frequently linked to an immunosuppressive microenvironment that facilitates tumor evasion of anti-cancer immunity. The cells that suppress the immune system such as regulatory B cells (Bregs),...
37.
Color differences of skin paddles using the free flap for autologous breast reconstruction in Asian patients
Nakatsuka K, Karakawa R, Yano T
Breast Cancer . 2024 Nov; 32(2):306-313. PMID: 39586891
Background: In this study, we aimed to evaluate color differences of the skin paddle in autologous breast reconstruction performed using the deep inferior epigastric artery perforator (DIEP) flap and the...
38.
Real-world incidence of and risk factors for abemaciclib-induced interstitial lung disease in Japan: a nested case-control study of abemaciclib-induced interstitial lung disease (NOSIDE)
Nakayama S, Yoshizawa A, Tsurutani J, Yoshimura K, Aoki G, Iwamoto T, et al.
Breast Cancer . 2024 Nov; 32(1):177-185. PMID: 39556171
Purpose: The exact incidence of and risk factors for interstitial lung disease (ILD), a serious side effect of abemaciclib, remain unknown in real-world settings. We examined the incidence of and...
39.
Development and validation of a predictive risk tool for VTE in women with breast cancer under chemotherapy: a cohort study in China
Xu Q, Li X, Yuan Y, Hu Z, Liang G, Wang Y, et al.
Breast Cancer . 2024 Nov; 32(1):154-165. PMID: 39549222
Objective: The incidence of venous thromboembolism (VTE) is significantly elevated in breast cancer patients, with a three-to-fourfold increase, and further escalates to sixfold in those undergoing chemotherapy. This study aims...
40.
Comprehensive characterization of invasive mammary carcinoma with lobular features: integrating morphology and E-cadherin immunohistochemistry patterns
Sung Y, Jeon T, Lee J, Oh J, An J, Kim A
Breast Cancer . 2024 Nov; 32(1):186-196. PMID: 39549221
Background: Breast cancer treatment prioritizes molecular subtypes over histologic types. However, considering the unique biological behavior of invasive lobular carcinoma (ILC), its diagnosis is crucial for patient management. Therefore, this...